Combination of Radiation Therapy & Anti-PD-1 Antibody SHR-1210 in Treating

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06056336` - Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma	Phase 2
Suspended	`NCT04084158` - A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.	Phase 2
Active, not recruiting	`NCT04242199` - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors	Phase 1
Not yet recruiting	`NCT05561699` - Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamous Cell Cancer	N/A
Active, not recruiting	`NCT04543617` - A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy	Phase 3
Recruiting	`NCT06190782` - Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor	Phase 3
Completed	`NCT05557955` - Identification of Breath Biomarkers in Esophageal Cancer
Recruiting	`NCT04045496` - A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors	Phase 1
Recruiting	`NCT04584008` - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics	N/A
Not yet recruiting	`NCT03766178` - Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma	Phase 2
Recruiting	`NCT02913066` - S-1 IMRT Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma	Phase 2
Completed	`NCT02399306` - Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma	Phase 3
Completed	`NCT01605305` - Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer	Phase 2
Not yet recruiting	`NCT05552651` - Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma	Phase 2
Recruiting	`NCT05520619` - Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)	Phase 2
Terminated	`NCT03251417` - Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma	Phase 2
Recruiting	`NCT05990231` - Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy	Phase 2
Recruiting	`NCT04644250` - Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma	Phase 2
Completed	`NCT02916511` - Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma	Phase 2
Terminated	`NCT04032704` - A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors	Phase 2

NCT number	NCT03187314
Study type	Interventional
Source	Hangzhou Cancer Hospital
Contact
Status	Completed
Phase	Phase 2
Start date	June 14, 2017
Completion date	June 30, 2019

Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms